An em­ploy­ee com­plaint at Eli Lil­ly's Branch­burg plant al­leges al­tered qual­i­ty con­trol docs amid FDA probe — re­port

Eli Lil­ly was one of the ear­li­est play­ers in the race for a Covid-19 an­ti­body, but a se­ries of set­backs at a New Jer­sey man­u­fac­tur­ing site have set back its ef­forts. Now, an in­ter­nal com­plaint re­port­ed­ly claims that a di­rec­tor at that site know­ing­ly fudged qual­i­ty con­trol docs right un­der the FDA’s nose.

An em­ploy­ee com­plaint from Eli Lil­ly’s man­u­fac­tur­ing plant in Branch­burg, NJ, al­leged that a di­rec­tor al­tered doc­u­ments hand­ed over to FDA reg­u­la­tors as part of an ef­fort to down­play se­ri­ous qual­i­ty con­trol is­sues amid the agency’s probe at the site, Reuters re­port­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.